John R Mccoy DeceasedGardena, CA

2013009, Apr 18, 2013

Oct 15, 2012

13/652463

Andy Ofer Goren - Newport Beach CA, US
John McCoy - Downey CA, US

C12Q 1/68
G01N 33/53
G01N 33/558
G01N 21/75

435 611, 435 25, 435 792, 435 71

Methods, processes, systems, and apparatuses are disclosed for predicting anti-androgen therapy response in the treatment of androgenetic alopecia based on a fluorometric assay and proteomics.

2013011, May 9, 2013

Nov 5, 2012

13/669435

Andy Ofer Goren - Newport Beach CA, US
John McCoy - Downey CA, US

A61K 8/60
A61K 31/7034
A01G 1/00
A61K 8/40
A61Q 17/04
B01J 19/12
A61N 5/06
A61K 31/24

424 60, 604 20, 2504921, 2504721, 47 581LS

Methods and compositions are disclosed for administering electromagnetic radiation (EMR), for therapeutic or cosmetic purposes, or for purposes of curing a polymeric material.

2013031, Nov 21, 2013

Jul 22, 2013

13/948090

John McCoy - Downey CA, US

Applied Biology, Inc. - Irvine CA

A61N 5/06
A61K 8/44
A61K 8/49

604 20, 424 60

Methods are disclosed for administering electromagnetic radiation (EMR), which may include filtering EMR from part of the EMR spectrum while allowing passage of EMR at a desired wavelength. A fluorescent component may be included, which absorbs EMR at one wavelength and emits EMR at the desired wavelength. Uses may include the treatment of acne. Pruritus may also be treated by allowing the passage to the skin of a particular UV wavelength from sunlight, which has an immunosuppressive effect, while protecting the skin from other harmful UV radiation.

2014002, Jan 23, 2014

Mar 15, 2013

13/843908

John McCoy - Downey CA, US

APPLIED BIOLOGY - Irvine CA

A61K 35/74
A61K 31/506
C12N 15/74

424 932, 424 934

A specific naturally occurring or genetically modified bacterial strain can be introduced into the hair follicle of patients suffering from androgenetic alopecia as to reduce the bioavailable extracellular testosterone and hence reduce the effect of androgens on the hair follicle.

3995833, Dec 7, 1976

Jul 23, 1975

5/598440

Jack McLaughlin - Orange CA
John R. McCoy - Carson CA

E04H 1714

256 59

Removable guard rail stanchion apparatus comprises a clamping portion adapted for clamping to surfaces of a floor edge and a vertical stanchion post having a lower end releasably locked in a socket fixed to the clamping portion. The clamping portions includes larger and smaller diameter vertical tubes, the smaller diameter tube being slidably connected inside the larger diameter tube by an elongate axial screw. Horizontally projecting clamping member is fixed to each of the two tubes. Turning of the axial screw telescopes the tubes and thereby adjusts the spacing between the clamping members which bear against horizontal floor edge surfaces. A dished washer, through which the clamping force is applied, flattens to give a visual indication when sufficient clamping force has been applied, an angle is provided on at least one of the clamping members to fit over a floor edge corner to prevent twisting of the clamping portion relative to the floor edge. In a variation, the two tubes comprising the clamping portion are horizontally disposed, and the clamping members depend therefrom to enable clamping of vertical edge surfaces. The stanchion part may be locked into the clamping portion socket by a removable pin, by a friction lock, or by a socket pin which fits into an inverted L-shaped edge cut out on the post.

2022029, Sep 22, 2022

Jun 10, 2022

17/806363

- Cheyenne WY, US
John McCoy - Downey CA, US

A61K 8/49
A61P 17/14
A61K 8/04
A61K 8/67
A61K 8/44

Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR-NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and/or keratinocyte cells. In addition, compositions and methods for increasing or decreasing the growth rate of hair follicles is disclosed by altering the intracellular pH. Additionally, methods for preparing a stable liposomal containing solution are described.

2021037, Dec 9, 2021

Jun 8, 2020

16/946158

- Irvine CA, US
John A. McCoy - Irvine CA, US

A61K 8/73
A61Q 5/02
A61K 8/49
A61K 8/31
A61Q 7/00
A61K 8/04

Compositions and methods are disclosed herein for treating female pattern hair loss with a topical composition used to remove minoxidil from the hairs. A method for diagnosing subjects in need of a topical composition used to remove minoxidil from the hair treatment and guiding the application of a topical composition used to remove minoxidil from the hair treatment are also described. Additionally, a method for diagnosing a subject at high risk for female pattern hair loss who will likely respond to topical composition used to remove minoxidil from the hair prophylactic treatment is described. A method for combining the composition described herein with topical minoxidil for androgenetic alopecia is described. In addition, cosmetic compositions are described as well as methods of improving the appearance of hair following application of minoxidil.

2021031, Oct 14, 2021

Mar 29, 2021

17/301188

- Irvine CA, US
John McCoy - Irvine CA, US

A61K 31/05
A61K 31/4709
A61K 31/277
A61K 31/4164
A61K 31/473
A61K 31/4439
A61K 31/4166
C07K 14/71
A61K 31/57
C07K 16/28
A61K 31/337
A61K 31/4155
A61K 31/437
A61K 33/18
A61K 31/167
A61K 31/58
C12N 15/113
A61K 38/09
A61P 31/14

The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV- infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-β inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV- infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-β inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.